Program
iptacopan
Also written as “Iptacopan”, “LNP023” and “Iptacopan (LNP023)”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA · Atypical Hemolytic Uremic Syndrome · Proteinuria · Macular Degeneration, led by Novartis.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 2512 open or running | phase 3since May 3, 2019 | Nov 30, 2017 | Dec 30, 2026phase 2 · NCT06388941 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Nov 30, 2017.
- Mar 23, 20212 phase 3 studiesNCT04817618, NCT04820530
- May 7, 2021Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT04889430 · 34 enrolled · United States, Brazil, China and more
- Sep 28, 2021Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT05086744 · 19 enrolled · United States, Germany, Italy and more
- Oct 13, 2021Phase 1 study in Hepatic ImpairmentNCT05078580 · 38 enrolled · United States
- Jan 28, 2022Phase 2 study in Macular DegenerationNCT05230537 · 168 enrolled · United States, China, Puerto Rico and more
- Nov 18, 2022Phase 3 study in Hemoglobinuria, ParoxysmalNCT05630001 · 52 enrolled · United States, France, Germany and more
- Feb 23, 2023Phase 3 study in ProteinuriaNCT05755386 · 106 planned · United States, Argentina, Brazil and more
- Mar 21, 2023Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT05795140 · 65 planned · Brazil, China, Czechia and more
- Jun 29, 2023Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT05935215 · 50 planned · China, France, Germany and more
- Feb 12, 2024Phase 3 study in Myasthenia GravisNCT06517758 · 146 enrolled · United States, Argentina, Australia and more
- Apr 17, 2024Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06388941 · 84 enrolled · United States, Argentina, Australia and more
- Jan 21, 2025Phase 2 study in Glomerulonephritis, IGANCT06797518 · 20 planned · United States, Argentina, Israel and more
- Mar 31, 2025Phase 3 study in Hemoglobinuria, ParoxysmalNCT06934967 · 12 planned · United States, Brazil, Colombia and more
- May 20, 2025Phase 3 study in Glomerulonephritis, IGANCT06994845 · 31 planned · United States, Argentina, Australia and more
Ahead
- Dec 30, 2026Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06388941
- Jan 29, 2027Primary completion: phase 3 study in ProteinuriaNCT04817618
- Apr 30, 2027Primary completion: phase 3 study in Myasthenia GravisNCT06517758
- Oct 18, 2027Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT04747613
TargetBeta
“Complement factor B inhibitor; Complement factor B inhibitor”ChEMBL 37, by rule
Other programs on CFB
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06994845Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Recruiting | Jun 28, 2030 | 31 |
| NCT06934967Hemoglobinuria, Paroxysmal · United States, Brazil, Colombia and more | 3 | Recruiting | Oct 14, 2031 | 12 |
| NCT06797518Glomerulonephritis, IGA · United States, Argentina, Israel and more | 2 | Recruiting | Nov 27, 2027 | 20 |
| NCT06388941Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States, Argentina, Australia and more | 2 | Active, not recruiting | Dec 30, 2026 | 84 |
| NCT06517758Myasthenia Gravis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 30, 2027 | 146 |
| NCT05935215Atypical Hemolytic Uremic Syndrome · China, France, Germany and more | 3 | Recruiting | Jul 21, 2028 | 50 |
| NCT05795140Atypical Hemolytic Uremic Syndrome · Brazil, China, Czechia and more | 3 | Recruiting | Jul 16, 2032 | 65 |
| NCT05755386Proteinuria · United States, Argentina, Brazil and more | 3 | Recruiting | Oct 27, 2028 | 106 |
| NCT05630001Hemoglobinuria, Paroxysmal · United States, France, Germany and more | 3 | Completed | Oct 17, 2024 | 52 |
| NCT05230537Macular Degeneration · United States, China, Puerto Rico and more | 2 | Completed | Aug 19, 2026 | 168 |
| NCT05078580Hepatic Impairment · United States | 1 | Completed | Jun 20, 2022 | 38 |
| NCT05086744Purpura, Thrombocytopenic, Idiopathic · United States, Germany, Italy and more | 2 | Terminated | Sep 20, 2023 | 19 |
| NCT04889430Atypical Hemolytic Uremic Syndrome · United States, Brazil, China and more | 3 | Completed | Apr 11, 2026 | 34 |
| NCT04820530Hemoglobinuria, Paroxysmal · China, France, Germany and more | 3 | Completed | Nov 2, 2022 | 40 |
| NCT04817618Proteinuria · United States, Argentina, Belgium and more | 3 | Recruiting | Jan 29, 2027 | 98 |
| NCT04747613Hemoglobinuria, Paroxysmal · United States, Brazil, China and more | 3 | Active, not recruiting | Oct 18, 2027 | 208 |
| NCT04557462Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Recruiting | Dec 4, 2030 | 540 |
| NCT04578834Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Completed | Sep 19, 2025 | 517 |
| NCT04558918Hemoglobinuria, Paroxysmal · United States, Brazil, Czechia and more | 3 | Completed | Sep 26, 2022 | 97 |
| NCT04154787Glomerulonephritis, Membranous · Argentina, China, Czechia and more | 2 | Terminated | Jan 20, 2023 | 37 |
| NCT03955445Glomerulonephritis, Membranoproliferative · United States, Argentina, Brazil and more | 3 | Recruiting | May 30, 2036 | 225 |
| NCT03896152Hemoglobinuria, Paroxysmal · Korea, Republic of, Malaysia, Singapore and more | 2 | Completed | Apr 7, 2020 | 13 |
| NCT03832114Glomerulonephritis · United States, France, Germany and more | 2 | Completed | Apr 23, 2021 | 27 |
| NCT03439839Hemoglobinuria, Paroxysmal · France, Germany, Italy | 2 | Completed | Apr 22, 2020 | 16 |
| NCT03373461Glomerulonephritis, IGA · Argentina, Australia, Belgium and more | 2 | Completed | Dec 29, 2020 | 112 |
How it is read
Names in the registry
- “Iptacopan”, 12 entries
- “LNP023”, 9 entries
- “iptacopan”, 4 entries
- “Iptacopan (LNP023)”, 2 entries
- “Iptcaopan 200 mg”, 1 entry
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 7 studies
- Glomerulonephritis, IGA, 5 studies
- Atypical Hemolytic Uremic Syndrome, 3 studies
- Proteinuria, 2 studies
- Macular Degeneration, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.